Puma Biotechnology (PBYI) Cash & Equivalents (2011 - 2026)

Puma Biotechnology's Cash & Equivalents history runs 16 years deep, the most recent figure standing at $36.2 million for Q1 2026.

• Quarterly Cash & Equivalents fell 42.58% year-over-year to $36.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.2 million (down 42.58% YoY) and the FY2025 annual result came in at $29.6 million, down 57.19% from the prior year.
• Cash & Equivalents was $36.2 million for Q1 2026 at Puma Biotechnology, up from $29.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $84.6 million in Q4 2023 and bottomed at $29.6 million in Q4 2025.
• A 5-year average of $63.3 million and a median of $63.9 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents increased 25.01% — and 2025, when it slumped 57.19%.
• Puma Biotechnology's Cash & Equivalents stood at $76.2 million in 2022, then increased by 11.0% to $84.6 million in 2023, then declined by 18.17% to $69.2 million in 2024, then slumped by 57.19% to $29.6 million in 2025, then grew by 22.13% to $36.2 million in 2026.
• Business Quant data shows PBYI's Cash & Equivalents at $36.2 million in Q1 2026, $29.6 million in Q4 2025, and $53.5 million in Q3 2025.